Our study shows how clinicians can reduce risk and increase effectiveness for oxycodone dosing by ( @ ) determining the patient 's likely metabolic response through testing a patient 's CYP@D@ phenotype , and ( @ ) calculating clinical pharmacokinetics specific to the patient 's CYP@D@ phenotype to design a personalized oxycodone dosing regimen .